Description:

CALGB 40503 RE-REGISTRATION WORKSHEET Tamoxifen or Letrozole With or Without Bevacizumab in Treating Women With Stage III or Stage IV Breast Cancer Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=2408A042-94BA-4908-E044-0003BA3F9857

Link:

https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=2408A042-94BA-4908-E044-0003BA3F9857

Keywords:
Versions (2) ▾
  1. 8/26/12
  2. 1/9/15
Uploaded on:

January 9, 2015

DOI:
No DOI assigned. To request one please log in.
License:
Creative Commons BY-NC 3.0 Legacy
Model comments:

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for:

Item comments for:

In order to download data models you must be logged in. Please log in or register for free.

Breast Cancer NCT00601900 Registration - CALGB 40503 RE-REGISTRATION WORKSHEET - 2551890v1.0

Registration to Bevacizumab Following Progression, Per Protocol Section 5.4 and 8.4

Header Module
Certification Of Eligibility/protocol Design
Is the patient eligible for open label Bevacizumab (Progression and initially received Placebo)
Re-registration Information

Similar models